Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Metformin Stories

Revealing The Secrets Of How Diabetes Drug Metformin Works
2013-11-04 07:28:51

redOrbit Staff & Wire Reports - Your Universe Online Researchers from McMaster University in Hamilton, Ontario have discovered how metformin, one of the world’s most commonly prescribed diabetes drugs, interacts with insulin in order to lower a person’s blood sugar. According to the study authors, approximately 120 million people, globally, with Type 2 diabetes use the medication to control their disease, including two million in Canada. While doctors had known that metformin...

2013-11-01 12:27:56

JDRF grant will fund novel research to evaluate efficacy and safety of metformin and insulin therapy in overweight adolescents ages 12 to 19 with type 1 diabetes. BOSTON, Nov. 1, 2013 /PRNewswire/ -- T1D Exchange, the first program of the new nonprofit organization Unitio, has received a $2.8 million research grant from JDRF to study the use of metformin--a drug used as first-line treatment for type 2 diabetes--in combination with standard insulin therapy in overweight adolescents...

2013-10-21 16:25:57

INCLINE VILLAGE, Nev., Oct. 21, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed (NASDAQ: DEPO) in exchange for a $240.5 million cash payment. PDL will receive all royalty and milestone payments due under the agreements until it has received payments equal to two times the cash payment made to Depomed, after which all...

2013-10-21 16:25:51

Cash to support future product acquisitions NEWARK, Calif., Oct. 21, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has sold its interests in royalty and milestone payments under its license agreements in the Type 2 diabetes therapeutic area to PDL BioPharma, Inc. for $240.5 million. Depomed intends to use the sale proceeds to acquire products that will drive long-term growth and build on the company's commercial expertise in pain and neurology. The...

2013-10-21 08:29:05

SAN DIEGO, Oct. 21, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today the completion of a 12-week Phase 2b study of NewMet(TM), a delayed-release formulation of metformin for the treatment of patients with Type 2 diabetes. Elcelyx previously reported that the study met its primary endpoint of statistically significant reduction in fasting plasma glucose at four weeks of treatment with NewMet compared to placebo. The 12-week data confirm the durability of the effect observed...

2013-09-18 23:02:15

Western University of Health Sciences' College of Pharmacy assistant professor Olivia J. Phung, PharmD, has published an article proposing that using a certain class of diabetes medication could potentially increase risk of heart attack and other cardiovascular problems. Pomona, CA (PRWEB) September 18, 2013 College of Pharmacy assistant professor Olivia J. Phung, PharmD, has published an article proposing that using a certain class of diabetes medication could potentially increase...

2013-09-17 08:31:27

SAN DIEGO, Sept. 17, 2013 /PRNewswire/ -- Elcelyx Therapeutics today announced that clinical advisor, John Buse, M.D., Ph.D., will present clinical data for NewMet(TM), a delayed-release formulation of generic metformin, in an oral presentation at the 49th Annual European Association for the Study of Diabetes (EASD) Meeting in Barcelona, Spain. Dr. Buse, Professor of Medicine and Director, Diabetes Care Center, Chief, Division of Endocrinology, Executive Associate Dean for Clinical Research...

2013-09-11 08:27:41

--Peer-Reviewed Publication Shows NM504 Eliminated Dose-Limiting GI Side Effects and Was Associated with Improved Blood Glucose Control in a Type 2 Diabetes Patient Treated with Metformin-- BROOMFIELD, Colo., Sept. 11, 2013 /PRNewswire/ -- MicroBiome Therapeutics LLC, (MBT), a biotechnology company developing pharmaceutical and medical food products that shift the human microbiome in specific ways for improved health, today reported publication of a case report suggesting a...

2013-09-10 08:31:20

TAIPEI, Sept. 10, 2013 /PRNewswire/ -- TWi Biotechnology, Inc., today announced that it has received an official notification of patent allowance for AC-201, TWi Biotechnology's lead drug candidate, from the United States Patent & Trademark Office. The granted patent, US patent number 8,536,152, covers AC-201's use as a combination therapy with other existing blood glucose lowering therapy agents to treat Type II diabetes. The patent is part of TWi Biotechnology's broad...

2013-09-09 16:24:22

NEWARK, Calif., Sept. 9, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced today it has expanded the geographic scope of its non-exclusive license agreement with a subsidiary of Merck for certain patents directed to metformin extended release technology for use in JANUMET(®) XR (sitagliptin and metformin hydrochloride (HCl) extended-release). The territory covered by the license agreement is now worldwide. Under terms of the agreement originally entered into in July 2009,...